



Connecting your treatments directly to patients

Direct-to-patient services for decentralized clinical trials

The typical clinical trial experiences a 30% patient dropout rate, which directly translates to increased risk and cost. According to patients, the study location and time spent on clinical visits are two of the top three dislikes of their overall clinical trial experience.¹ These concerns can be eased or eliminated with decentralized clinical trials (DCTs).

DCTs have been an option for drug makers since the 1990s, and Thermo Fisher Scientific's direct-to-patient services have been there from the start, with support now offered in 50+ countries. The challenges of COVID-19 combined with ubiquitous digital technologies brought about the swift adoption of DCTs by many clinical trial sponsors and have enabled the continued shift in point of care into the patient's home. It is recognized that there remain differing levels of comfort and readiness for pursuing DCTs, not only for drug developers but also for the clinical sites and patients involved. That's why we offer services to support traditional clinical trial channels, hybrid trials, and 100% decentralized trials.

DCTs have been an option since the 1990s, and Thermo Fisher Scientific's direct-to-patient services have been there from the start.


Likelihood of decentralized clinical trials increasing within the next two years.



Momentum is expected to continue post COVID-19 with 85% of survey respondents anticipating an increase of DCTs over the next two years.²

Maximizing flexibility: direct-to-patient service offerings

Direct-to-patient options at a glance



Clinical site-to-patient services	Depot-to-patient services	Pharmacy-to-patient services
This entails making planned shipments of clinical materials required for a study—including IMP, other study drugs, and ancillaries—from a clinical site to a patient's home.	This enables sponsors to leverage depot stock to make planned shipments of IMP and ancillaries to the clinical site and/or directly to the patient's home.	This allows sponsors to fulfill orders from a central pharmacy for patients participating in clinical trials in the US and EU. Experienced and registered pharmacists service prescription fulfillment.

All direct-to-patient services include:

- Compliance with HIPAA, GDPR, and PIPL regulations, including ongoing risk assessments
- Global network of qualified carriers for shipments directly to the patient's home
- Cold chain management and traceability services across temperatures and classifications
- IMP and non-IMP shipments (supportive medications and ancillaries sourcing and management) options
- Direct-to-patient contact center for patients and clinical sites
- Shipment coordination with the patient, clinical site, and home health care nurse (if applicable)
- Continuous monitoring, notifications and communication in multiple languages to patient and clinical site/home nursing provider as required

As a rule of thumb, if a patient visit does not require the presence of a physician and the equipment required is portable, the visit can be conducted by a nurse, if approved by the Institutional Review Boards.

Clinical site-to-patient global service offering

Ability to ship to key countries approved and vetted by our regulatory experts



One provider with one contract to cover all your traditional clinical trials supply and direct-to-patient needs

50+ countries approved

Additional countries can be assessed per customer request



Make your decentralized clinical trial a success with direct-to-patient services. To learn more about ensuring your clinical trial satisfies the needs of your patients, watch this informative webinar.

Contact your local Thermo Fisher Scientific representative to learn more.

1. CISCRRP 2017 Perceptions & Insights Study: The Participation Experience, <https://www.ciscrrp.org/wp-content/uploads/2019/06/2017-CISCRRP-Perceptions-and-Insights-Study-Participation-Experience.pdf>

2. Informa Connect Decentralized Clinical Trials in 2020, Global Industry Survey, <https://pharmaintelligence.informa.com/resources/product-content/sitecore/shell/-/media/informa-shop-window/pharma/2020/covid-24-campaign/slides/decentralized-clinical-trials-in-2020.pdf>